Scientists hunt for early clues to prostate cancer drug resistance
NCT ID NCT07352748
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study looks at why hormone therapy eventually stops working in advanced prostate cancer. Researchers will take tumor samples from 30 patients before and during treatment to study changes in immune cells and cancer markers. The goal is to find early signs of resistance and identify new targets for future therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal early signs of drug resistance and point toward new treatment targets for advanced prostate cancer.
- What could go wrong
- This is a small, early observational study (30 participants) that does not test a new treatment. It may not lead to direct patient benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Università di Verona
Verona, VR, 37134, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy